SLC5A2 and cardiovascular disorder: However, in the subgroups for obesity [aHR 1.08, 95%CI 0.85–1.35) and SGLT2 inhibitors use (aHR 1.05, 95%CI 0.82–1.35), GLP-1 RAs were associated with a non-significantly higher risk of cardiovascular disease (Additional file 1: Table S4).